증권선물위원회는 삼성바이오로직스가 투자주식을 공정가치로 임의평가해 4조5000억원을 과대계상했다고 결론내렸다.
The Securities and Futures Commission concluded that Samsung Biologics overvalued KRW 4.5 trillion by randomly evaluating its investments at fair value.